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Ex vivo labeling of neural stem cells for Magnetic 
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Neural stem cells are promising candidates for the treatment of brain-related diseases 
because of their differentiation and migration potential. To be able to better predict 
their therapeutic efficacy, and as such to limit the resources that are needed for 
optimization of treatment protocols, it is important to study the in vivo behavior of 
neural stem cells following transplantation. Prior labeling of stem cells, using iron 
oxide nanoparticles, allows for their visualization by magnetic resonance imaging 
(MRI). Through the optimization of nanoparticles’ characteristics, such as size and 
surface charge, efficient and non-toxic cell labeling procedures may be achieved. Here 
we show that C17.2 neural stem cells that are labeled with large-sized, i.e. 500 nm, iron 
oxide particles provide a better signal in MRI than cells labeled with small particles of 
100 nm in diameter. The cellular uptake of large-sized iron oxide particles, which by 
itself is limited, can be enhanced through the use of positively charged lipids and 
polymers, such as lipofectamine and JetPEI, respectively.  The approach of cationic 
vector-enhanced cell labeling substantially improves the imaging quality of neural stem 



















Stem cell therapy is a promising strategy for the treatment of human disease. Currently, 
the best known approved therapy in this regard is bone marrow transplantation, i.e., the 
transplantation of haematopoietic stem cells to treat leukemia, and other types of 
cancers and blood disorders [1-3]. In the future, it is anticipated that stem cell therapy 
may be further expanded to the treatment of a variety of other diseases, including 
cancer, and neurodegenerative diseases, such as Parkinson’s disease, and multiple 
sclerosis [4-6]. For the treatment of brain-related diseases, neural stem cells are the 
preferred treatment modality as they have the intrinsic potency to differentiate into all 
three brain cell types, i.e. neurons, astrocytes, and oligodendrocytes. Moreover, neural 
stem cells have the capacity to migrate to the brain pathology following systemic 
administration or brain implantation [7, 8]. To investigate the (migratory) behavior of 
stem cells after transplantation in vivo, noninvasive methods that allow for the real-
time visualization and tracking of transplanted stem cells, including positron emission 
tomography (PET), single-photon emission computed tomography (SPECT), magnetic 
resonance imaging (MRI), and optical microscopy are being developed [9, 10].  
However, laborious and time-consuming experiments are commonly needed to 
establish a correct treatment protocol for each disease. For example, the proper timing 
of stem cell application, the route of administration, the adequate number of cells, need 
to be determined. A common way to assess the efficacy of a therapy is by the 
evaluation of symptom relief. However, knowledge on earlier steps in therapy, 
including the body distribution of stem cells, can provide great help in speeding up the 
development and hence the efficiency of such a treatment.  
Magnetic Resonance Imaging (MRI) is widely used in hospitals as a noninvasive 
technique to obtain three-dimensional images inside the human body. Because MRI 
provides good contrast between the different soft tissues, it is an ideal approach for 
imaging the brain [11]. In addition, lack of irradiation exposure to stem cells, thus 
avoiding potential radiation damage, makes MRI the favorable imaging method 
compared to nuclear medicine techniques like positron emission tomography and 
single photon emission computed tomography.  
In MRI, the electromagnetic flux that is produced by the relaxation of proton spins in a 
strong electromagnetic field, is measured and translated into images [12]. There are 
two types of proton relaxation pathways, resulting in two types of MR images, i.e., T1- 
and T2-weighted. T1-weighted MRI is based on the longitudinal relaxation time of the 
excited protons, whereas T2-weighted MRI is based on the transverse relaxation time. 
The use of MRI contrast agents may further improve MR images. Paramagnetic 
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contrast agents, mostly gadolinium complexes, enhance the signal in T1-weighted 
MRI, whereas superparamagnetic contrast agents like iron oxide particles reduce the 
T2 signal [13, 14]. 
It has been proposed that an increase in the diameter of iron oxide particles will 
improve MRI contrast, because of the larger magnetic core within large particles 
compared to small particles [15]. However, in general larger-sized particles become 
less efficiently internalized by cells [15-17]. To overcome this drawback, we 
investigated whether commonly used transfection agents, like those based on cationic 
lipids and polymers for introducing plasmids into cells, could similarly facilitate and 
thus improve the delivery of negatively charged 100 nm and 500 nm iron oxide 
particles into C17.2 neural stem cells. The short term toxicity of particles was assessed 
by MTT assay, while the long term stability of labeling was investigated in dividing 
and non-dividing cell populations, and upon cell differentiation. The effect of 
nanoparticle iron core size on MRI signal of labeled neural stem cells was investigated 
using a clinically available MRI scanner. 
 
Materials and Methods 
Cell line 
The C17.2 murine neural stem cell line, kindly provided by Dr. Evan Snyder (Harvard 
Medical School, Boston, MA), was grown in high glucose Dulbecco's modified Eagle's 
medium (Invitrogen, the Netherlands) supplemented with 10% fetal calf serum 
(Bodinco B.V. The Netherlands), 5% horse serum (Invitrogen, the Netherlands), 100 
mg/L ampicillin (Invitrogen, UK), and 100 mg/L streptomycin (Invitrogen, UK)  at 
37°C under a 5% CO2 atmosphere, and passaged twice a week (1:10 dilution).  
 
Superparamagnetic nanoparticles  
100 nm fluidMAG-UC containing 66 wt% of iron (100 nm iron oxide particles), 500 
nm screenMAG-Hydroxyl containing 23 wt% iron (500 nm silica particles loaded with 
iron oxide) and 500 nm screenMAG-PEI beads containing 23 wt% of iron (PEI-
functionalized silica particles loaded with iron oxide) were purchased from Chemicell, 
Germany. 
 
Quantification of cellular viability by MTT assay 
The viability of C17.2 cells that had been exposed to increasing amounts of iron oxide 
particles was evaluated by performing a 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl 
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tetrazolium bromide (MTT) assay (Sigma).  In short, cells were plated at 40.000 cells / 
well in a 48-wells plate. One day later cells were treated in triplicate with: 1, 4 and 8 μg 
of 100 nm iron oxide particles; 3, 10 and 20 μg of 500 nm iron oxide particles, and 3, 
10 and 20 μg of PEI iron oxide particles in 0.2 mL complete feeding medium, i.e, 
corresponding to 5, 20 and 40 μg 100 nm iron oxide particles/mL and 15, 50 and 100 
μg 500 nm and PEI iron oxide particles/mL, for 4 h, washed twice with HBSS and 
incubated in complete feeding medium over the next 20 hours. Alternatively, the cells 
were exposed to the iron oxide particles during 24 h. Untreated cells were used as a 
control. During the final 3 hours of the incubation, the samples were exposed to 50 μL 
MTT solution (5 mg/mL in PBS). Thereafter the plate was centrifuged for 15 min at 
800 g (RT), the medium was removed, and the formazan crystals were dissolved in 0.5 
mL of DMSO. The optical density of each well was measured using a multiwell plate 
reader (uQuant, Bio-Tek Instruments, Inc, USA) at 520 nm.  
 
Loading of C17.2 cells with iron oxide particles 
Cells were plated at 0.3 x 10
6
 cells /well in twelve wells plates. The next day, cells 
were incubated for 4h and 24h with 20 μg / well of 100 nm iron oxide particles (13.2 
μg iron /mL), 50 μg / well of 500 nm iron oxide particles (11.5 μg iron/mL),  and 50 μg 
/ well of PEI iron oxide particles (11.5 μg iron/mL). In addition, prior to the incubation 
with the cells, 100 nm and 500 nm iron oxide particles were complexed with 
Lipofectamine 2000 (Invitrogen, UK) and JetPEI (Polyplus transfection, France) 
transfection reagent. Next, the cells were washed two times with HBSS and left for an 
additional 24 hours in complete medium. Cells were counted at this point to examine 
the influence of the transfection agents on cell proliferation. The ratios of iron oxide 
particles and transfection agents that showed the optimal cell labeling without affecting 
cell proliferation (Table 1) were used in further experiments.  
 
Qualitative measurement of intracellular iron content by Prussian blue 
staining 
Following an incubation of the C17.2 cells with the different types of 
superparamagnetic iron oxide particles, a Prussian blue staining was performed to 
visualize the amount of iron oxide within the cells. Cells were seeded on coverslips in 
12 wells plates and incubated with iron oxide particles for 4 h and 24 h.  Cells were 
washed three times with HBSS to remove unbound iron oxide particles, and fixed with 
4% PFA.  Thereafter, cells were incubated for 30 min with a 1:1 mixture of fresh 5% 
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solution of potassium hexacyanoferrate (II) trihydrate (Sigma – Aldrich, Steinheim, 
Germany) and 5% hydrochloric acid (VWR Prolabo, Briare, France). After 3 times 
washing in distilled water, the cells were counterstained for 10 min with nuclear fast 
red (Sigma – Aldrich, Steinheim, Germany). 
 
Quantification of intracellular iron content by Tiron assay 
The iron content of the cells after loading with iron oxide particles was measured using 
a chelating agent, Tiron (4,5-Dihydroxy-1,3-benzenedisulfonic acid, disodium salt 
monohydrate, Acros Organics, Geel, Belgium). A reaction of Tiron with Fe
3+
 gives a 
colored product that can be spectrophotometrically measured at 490 nm (modified 
method by Yoe and Jones [18]). Following incubation with iron oxide particles, cells 
were trypsinized and resuspended in 1 mL HBSS. A 50 μL sample was prepared for 
cell counting and the rest of the suspension was digested overnight with an equal 
volume of analytical grade nitric acid (65% solution in water, Acros Organics, Geel, 
Belgium) to disrupt the cells plus iron oxide particles. A standard curve ranging from 0 
– 20 μg / mL Fe
3+
 was prepared from a 1 mg / mL Fe
3+
 stock solution. Similar to the 
cell samples, the iron stock solution and standard curve samples were prepared in 32% 
nitric acid. A 0.5 mL sample of either the cell lysate or standards was mixed with 0.5 
mL 10 M NaOH, 0.1 mL 1 % Tiron and 1 mL 0.2 M sodium phosphate buffer, pH 9.5. 
Absorption at 490 nm was read within 30 min in a multiwell plate reader (uQuant, Bio-
Tek Instruments, Inc, USA). 
 
Stability of cell labeling with iron oxide particles 
A cell label can be lost simply by dilution due to cell division and/or by active cellular 
exocytosis. Since cell division is expected to be low during migration in vivo, the 
stability of cell labeling was measured in non-dividing C17.2 cells, i.e., in order to 
determine active cellular exocytosis of iron oxide particles. Cells were plated in 12-
wells plates at 0.4x10
6
 cells per well in 1 mL of complete medium. The next day cells 
were incubated for 4 h with iron oxide particles at the conditions shown in Table 1. 
After two times washing with HBSS, cells were incubated in the absence and presence 
of the proliferation inhibitor TPI (tubulin polymerization inhibitor II, Calbiochem, San 
Diego, USA) at a concentration of 0.05 μM in complete medium for 24 and 72 hours 
[19]. At the end of the incubation period, the cell number was counted using a counting 
chamber and the cellular iron content was determined by the Tiron assay.  
The optimal concentration of TPI at which a non-dividing cell population was 
established without cellular toxicity was determined in a separate experiment. 
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Stability of iron labeling during cell differentiation 
For differentiation studies the cells were plated and loaded with particles on coverslips 
in 12 wells plates. 24 hours after particle loading complete feeding medium was 
replaced with differentiation medium, i.e., DMEM/F12 medium (GIBCO) 
supplemented with 25μg/mL N2 (GIBCO). The samples were fixed in 4% 
paraformaldehyde 5 days later and immunostained for the neuronal marker anti-βIII 
tubulin (Tuj1; monoclonal, 1:500, Covance, Richmond, CA). 
 
MRI of C17.2 cells loaded with iron oxide particles 
C17.2 neural stem cells were loaded for 4 h with 100 nm and 500 nm iron oxide 
particles complexed with Lipofectamine 2000, and 500 nm PEI iron oxide particles as 
described under Loading of C17.2 cells with iron oxide particles. Alternatively the 
cells were loaded with half of the amount of prepared complexes. The next day the 







 cells/μL. 0.5 mL tubes were filled with 100 μL of each cell suspension and 
covered with 200 μL of 2% agarose. Tubes filled with non-labeled cells were prepared 
as well. In order to avoid artifacts in MRI from surrounding air the tubes were placed 
in a plastic container filled with 2% agarose gel.  MR imaging was performed using a 
clinical 3T Philips Intera MR-scanner with SENSE head-coil (Royal Philips 
Electronics, Amsterdam, The Netherlands). The phantom was imaged by T2W-TSE 
sequence using CLEAR  (Constant LEvel AppeaRance) coil uniformity correction 
technique. Imaging parameters were as follows: repetition time (TR) 3000 ms, echo 
time (TE) 120 ms number of slices 40, field of view (FOV) 150 mm, voxel size 
0.29x0.29x1.1mm, scan time 72s.   
The data were analyzed by AMIDE software [20] upon conversion of the raw data into 
Analyze format. The signal intensity (si) of the cells was measured by placing a 3D 
region of interest (ROI) in the suspension of cells labeled with iron oxide particles (B) 
or control cells (C). All ROIs were > 70 voxel. The signal intensity ratio (contrast) of 
iron-labeled cells was calculated from the measured signal intensities using the 








Effect of PEI iron oxide particles on the viability of NSCs 
In order to verify whether iron oxide particles might cause cellular toxicity, the C17.2 
neural stem cells were exposed to increasing concentrations of these particles up to 
24h. Specifically, cells were incubated with 5, 20 and 40 μg/mL of particles with a 
diameter of 100 nm, 15, 50 and 100 μg/mL of particles with a diameter of 500 nm, and 
with PEI-coated iron oxide particles (500 nm). Following incubation for 4h (Fig 1A) or 
24h (Fig. 1B) with low, medium, and high concentrations of 100 nm and 500 nm iron 
oxide particles, the cellular viability remained virtually unaffected. Only at the highest 
concentration of the PEI coated particles (100 µg/ml) a minor but statistically 
significant decrease in cell viability after 24h of incubation (p < 0.05 [p=0.015]) was 
apparent, suggesting that these high concentration represented the limit of tolerance. 
Therefore, in the next experiments, C17.2 neural stem cells were incubated with the 
medium concentration of all three types of iron oxide particles, i.e., 20 µg/mL of 100 





Figure 1: Cellular toxicity of 100 nm, 
500 nm and PEI iron oxide particles. 
To check for toxicity of particles, cells 
were exposed to 5, 20 and 40 μg of 
100 nm particles/mL and 15, 50 and 
100 μg of 500 nm and PEI particles/ 
mL during 4h (a) or 24 h (b). The 
results were evaluated by MTT assay. 
Concentrations of particles were 
marked as low (5-15 μg/mL), medium 
(20-50 μg/mL) and high (40-
100μg/mL). The results are presented 
relative to control cells. Student t-test 
was performed for each condition 
against control. * - p<0.05. 
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Efficiency of NSCs labeling, as accomplished with 100 nm and 500 nm iron 
oxide particles 
C17.2 NSCs were incubated with 100 nm and 500 nm iron oxide particles for 4h and 
24h. After 4h of incubation, the cells showed an efficient uptake of the 100 nm iron 
oxide particles, as was visualized by Prussian blue staining (Fig. 2a). After another 20 
h of incubation (total 24h), no visually distinguishable additional increase in the 
cellular uptake of the 100 nm particles could be observed (Fig. 2b), as confirmed by 
quantitative measurements of the Fe content (Fig.2e). Incubation of the cells with 500 
nm iron oxide particles for 4h resulted in a substantially lower cellular iron content 
than following an incubation with 100 nm particles (Fig.2c vs. 2a), consistent with 
quantification of the Fe uptake by the cells (Fig.2e). However, after 24h the cells 
showed a pronounced increment in the uptake of the 500 nm particles (Fig. 2d vs. 2c) 
and quantitatively, the iron content of the cells was two-fold higher than in the case of 













Transfection agents improve cell labeling with iron oxide particles 
To optimize iron oxide labeling conditions in terms of speed concerning particularly 
500 nm particles, we next investigated whether the complexation of the (negatively 
charged) iron oxide particles with positively charged transfection agents may accelerate 
iron oxide internalization by NSCs. Here, complexation with the transfection agents 
Lipofectamine 2000 (LF2000) and JetPEI was used for charge neutralization of the 
iron oxide particles, using the optimized labeling conditions as shown in Table 1. In 
addition, we compared these data with commercially available PEI-coated iron oxide 
particles. As can be seen in Figure 3, relative to non-coated iron oxide particles (Figs 
3a and d), the complexation of 100 nm and 500 nm particles with LF2000 and JetPEI 
Figure 2. Uptake of 100 nm and 500 nm iron oxide particles by C17.2 neural stem cells. 
Cells were incubated for 4 h and 24 h with iron oxide particles and subsequently stained with 
Prussian blue: A. 100 nm particles 4h incubation; B. 100 nm particles 24h incubation; C. 500 
nm particles 4h incubation; D. 500 nm particles 24h incubation. Quantification was 
performed using Tiron assay (E).  
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significantly increased internalization by the NSCs (Fig. 3 a-c (100 nm) and d-f (500 
nm). The commercially available 500 nm PEI iron oxide particles were also readily 
internalized (Fig. 3 g). Since the Prussian blue staining reaction may not properly 
reflect quantitative aspects of the extent of particle internalization, staining being 
influenced by the particle’s surface composition, a quantitative analysis of the cellular 
iron contents was performed using the Tiron assay. As shown in Fig. 3h, the cellular 
iron content as determined by the Tiron assay, confirms that both transfection agents 
improve the labeling of C17.2 NSC with iron oxide particles. Thus, compared to the 
bare iron oxide particles, JetPEI increased the cell labeling with 100 nm and 500 nm 
particles with a factor of approximately 2 and 4, respectively, while Lipofectamine 
2000 increased the cell labeling with 100 nm particles approximately 1.5 times, and 
that of 500 nm particles approximately 3 times. Cell labeling with the commercially 
available PEI particles (500 nm) gave similar results as the labeling with 100 nm and 
500 nm particles, complexed with JetPEI (Fig. 3h). Furthermore, it is noteworthy that 
the relative uptake of the added dose was fairly efficient, in that labeling with JetPEI-
derivatized particles resulted in  a cellular uptake of 76.3 ± 6.8 % of the administered 
dose in case of 100 nm iron oxide particles and 77.3 ± 9 % dose in case of 500 nm iron 























100 20 13.2 4 2 
500 50 11.5 5 5 
Table 1. Labeling conditions for C17.2 neural stem cells with 100 nm and 500 nm iron oxide 
particles. The amount of particles, their iron content, and the amount of transfection agents used 













Loss of iron label from NSCs is due to cell division 
For monitoring iron-labeled NSCs in vivo by MRI, it is important to assess the stability 
of the label in terms of it properly reflecting the fate of the labeled cell, rather than its 
fate per se. When NSCs were incubated for 24 h and 72 h following their labeling with 
iron oxide particles, the iron content expressed per cell decreased (Fig. 4, 24h control 
and 72h control; cf. with Fig 3h). The seemingly time-dependent decrease in iron 
content was shown to occur, irrespective of the physical nature of the iron oxide 
particles applied. Strikingly, the time in which the iron content showed a two-fold 
decrease, as expressed per cell, exactly correlates with the cell doubling time of C17.2 
NSCs, i.e., 16h. Therefore, the apparent decrease in iron content as expressed per cell 
over time can be ascribed to ‘the natural dilution’ of the iron oxide particles within the 
Figure 3. Influence of LF2000 and JetPEI on cell labeling efficiency with 100 nm, and 500 
nm iron oxide particles. C17.2 neural stem were incubated with 20 μg/mL 100 nm particles 
or 50 μg/mL 500 nm particles for 4 h. Iron oxide particles within the cells were visualized by 
Prussian blue staining: A. 100 nm particles; B. 100 nm particles complexed with 
Lipofectamine 2000; C. 100 nm particles complexed with JetPEI; D. 500 nm particles; E. 500 
nm particles complexed with Lipofectamine 2000; F. 500 nm particles complexed with 
JetPEI; G. PEI particles. The amount of iron was quantified by Tiron assay (H). 
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cells that occurs during cell division. To obtain further support for this notion, a non-
dividing cell population was established after labeling of the cells with iron, using the 
tubulin polymerization inhibitor TPI. When these cells were subsequently incubated 
over time, the iron content, expressed per cell in this non-dividing culture remained 










Stability of cell labeling during differentiation 
Another important feature of a neural stem cell marker for in vivo use is that it should 
not negatively influence stem cell differentiation into various brain cell types. This was 
examined next. C17.2 NSCs were labeled with iron oxide particles and subsequently 
allowed to differentiate following their culturing in differentiation medium. 
Immunostaining of the differentiated cells for Tuj1, a neuronal marker, showed that the 
amount of C17.2 cells that differentiated into neurons was similar for untreated cells 
and cells treated with the different types of iron oxide particles. Moreover, all neurons 
were labeled with iron oxide particles upon differentiation (Fig. 5 a-f arrowheads). The 
iron oxide particles mostly appeared in the soma. Occasionally, they were found in 
neurite outgrowths (Fig 5 c, arrow). Apparently, the presence of the iron particles does 
not interfere with the differentiation of NSCs into neurons. Likewise, the 
differentiation of NSCs into astrocytes was unaffected by the presence of iron oxide 
nanoparticles (not shown). 
Figure 4. Stability of cell labeling with iron oxide particles in a non-dividing cell 
population. C17.2 neural stem cells were loaded with iron oxide particles as described in 
materials and methods, washed, and incubated for 24 and 72 hours in complete medium 
(control) or in medium supplemented with 0.05 mM tubulin polymerization inhibitor II 
(TPI), which generates a non-dividing cell population. At the end of the incubation 









Effect of particle size on ability to visualize labeled cells 
Finally, an MRI phantom was prepared as described in Materials and Methods to detect 
the differences in signal intensities from cells containing equal amounts of iron by 
labeling with 100 nm and 500 nm iron oxide particles complexed with Lipofectamine 
2000 as well as 500 nm PEI particles, using the predetermined conditions. With a 
clinically available MRI scanner and using the settings as specified in the Materials and 
Methods, cells labeled with small- and large-sized particles were easily detectable by 
eye at a number of 10
3
 cells/μL (Fig. 6 a and b). Better contrast came from cells that 
were labeled with 500 nm particles compared to 100 nm particles regardless the 
amount of loaded particles (Fig. 6 a and b). This was confirmed by quantification of the 
data, as shown in Figure 7.  At a concentration of 10
2
 cells/µL the contrast 
enhancement in MRI is negligible for cells labeled with all types of iron particles. In 
samples with 10
4
 cells /μL the difference in contrast enhancement between 100 nm and 
500 nm iron oxide particles cannot be distinguished due to saturation of the signal.  
Figure 5. Stability of cell labeling with iron oxide particles during cell differentiation. 
C17.2 cells were loaded with iron oxide particles and subsequently allowed to differentiate, 
as described in the materials and methods. Cells were immunostained for the neural marker 
Tuj1. Labeling conditions are as indicated within the figure.  
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Figure 6. Visualization of iron-labeled 
cells with MRI (phantom). C17.2 neural 
stem cells were labeled with 100 nm 
and 500 nm iron oxide particles 
complexed with Lipofectamine 2000, 
and 500 nm PEI beads, at the indicated 
concentrations. Three different 
concentrations of  labeled cells were 
suspended in 2% agarose and imaged by 
T2W-TSE sequence with CLEAR (A). 
In (B) cells incubated with half the 
amount of iron oxide particles as 
compared to cells in (A) are visualized. 
Figure 7. Signal intensity ratios 
(contrast) of neural stem cells 
labeled with different iron oxide 
particles. Neural stem cells were 
labeled with similar amounts of iron 
by incubation with 100 nm and 500 
nm iron oxide particles complexed 
with Lipofectamine 2000, and 500 
nm PEI iron oxide particles. The 
resulting contrast enhancement in 
MRI was calculated from the images 
as shown in Figure 6 (A,B). 
Reduction of the cellular iron 
content by incubating the cells with 
half the amount of iron oxide 
particles results in a reduction in 






Labeling of neural stem cells with iron oxide particles allows for their in vivo tracking 
by MRI. Here we show that C17.2 neural stem cells can be labeled with commercially 
available 100 nm and 500 nm iron oxide particles. The uptake of large-sized (500 nm) 
particles by NSCs, although initially slower than that of small-sized (100 nm) particles, 
after 24 h shows a higher total capacity (Fig. 2).  
Prior complexation of the iron oxide particles with the transfection agents LF2000 and 
JetPEI enhances the cellular uptake of the particles. Particularly, the large-sized 
particles benefit from complexation by transfection agents in the sense that their 
intrinsic slow internalization rate drastically improves upon neutralization of their 
anionic charge (cf. Figs. 2e and 3h). In parallel with an enhancement in internalization 
rate the extent of internalization is improved. For the 100 nm particles, complexation 
with transfection agents shows a less pronounced effect on rate and extent of 
internalization than for the larger particles. Importantly, in cells that are labeled with 
100 nm and 500 nm iron oxide particles complexed with LF2000 and JetPEI, the iron 
oxide particles are not present at the cell-surface but localize intracellularly, as can be 
concluded from their perinuclear distribution (Fig. 3, b,c and e-f). Accomplishment of 
intracellular labeling is a critical requirement since a surface-bound magnetic probe is 
likely to interfere with cell-tissue interactions and/or may detach from the cell 
membrane and be taken up by other cells in vivo [22]. The latter would result in false 
positive signals in MRI.  
The labeling conditions that result in effective contrast enhancement of the cells in 
MRI are non-toxic, as was shown by MTT assay (Fig. 1) and unchanged cell division 
time upon labeling. In addition, the cells retain their differentiation capacity upon 
labeling with iron oxide particles (Fig. 5). Notably, the iron labeling in C17.2 neural 
stem cells proved to be stable in a non-dividing cell population. As the stem cells are 
expected to show little cell division during their in vivo migration, no loss of iron 
signal will occur upon their in vivo administration, thus allowing detection of the iron-
labeled stem cells by MRI for prolonged periods of time.  
Finally, by the use of transfection agents the uptake of large-sized iron oxide particles 
by C17.2 neural stem cells was made as efficient as the uptake of small-sized particles, 
as was measured from the cellular iron content (Fig. 3h). Complexation of iron oxide 
particles with transfection agents, as well as the covalent attachment of PEI to the 
particles gave similar results. This allowed for a comparative analysis of the MRI 
signal strength of cells labeled with iron oxide particles with a big magnetic core and a 
small magnetic core. It turns out that an increase in the magnetic core of the iron oxide 
particles leads to an increase in MRI contrast enhancement (Fig. 7). Instead of using 
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small superparamagnetic iron oxide nanoparticles, efforts should therefore be aimed at 
optimizing cell labeling with large-sized nanoparticles. The 500 nm iron oxide particles 
that were used in this study were calculated to have a magnetic core of ~330 nm and a 
shell of 85 nm. An increase of the magnetic core or, similarly, a reduction of the shell 
thickness would result in increased iron content per particle, and may further increase 
MRI signal of labeled cells [23]. Interestingly, it has been shown that although larger 
particles may have higher relaxivity per particle compared to smaller particles, their 
relaxivity per iron basis may actually be lower, as caused by differences in domain size 
and clustering of the iron oxide crystals within the particles [15]. Therefore in the 
future particular attention should also be paid to the internal composition/structure of 
large iron oxide particles for MRI purposes.  
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